Under the agreement, Adicon will provide biopharmaceutical companies conducting clinical trials in China access to Guardant's tissue and liquid biopsy tests.
The RNAscope ISH Probe High Risk HPV test detects E6/E7 mRNA and is intended to help inform treatment selection in oropharyngeal squamous cell carcinoma patients.
In addition to detecting the viruses that cause viral meningitis and encephalitis, the test kit can be used to identify herpes viruses.
The agency had originally planned to delete unspecified diagnosis codes for certain cancer tests covered under a national coverage decision.
The test detects variants in the POMC, PCSK1, and LEPR genes to identify individuals eligible for treatment with Rhythm Pharmaceuticals' recently approved Imcivree.
The company plans to launch a commercial product sometime after completing its currently ongoing Series A funding round.
With electronic health record and tumor panel sequence data from tens of thousands of cancer cases, researchers tallied relationships between gene alterations and patient outcomes.
The companies will build a diverse research cohort with multiomics data and apply AI as they seek to improve diagnostics and advance drug discovery.
The firm also plans to submit the assay to the US Food and Drug Administration for Emergency Use Authorization in the coming weeks.
Analysis of 7,500 patients showed one-third had potentially actionable mutations and 10 percent were misdiagnosed, prompting calls for greater NGS use in this setting.
Scientists from the University of Florence in Italy applied nanopore sequencing to effectively detect known copy number variants in a small cohort of patients.
The PCR-based assay uses an extraction-free multiplex reagent to test orthopoxvirus and monkeypox gene targets in skin lesion samples.
The San Jose, California-based infectious disease diagnostics company said it will use the funds to scale its production capacity and to add to its menu of tests.
The company plans to test and share genetic health risk data with 100,000 participants and their providers, aiming to improve patient care and outcomes.
The companies will codevelop, validate, and commercialize a companion diagnostic for Acrivon's targeted DNA damage response inhibitor therapy, ACR-368.
Under the agreement, Proteomics International has the right to use the markers to develop and commercialize a blood-based early detection test for esophageal cancer.
BioGX previously helped develop a monkeypox and orthopoxvirus assay on the GeneXpert that was validated on clinical samples in 2017.
The new assay makes a number of modifications to enhance the sensitivity of the CRISPR reaction and allow detection of rare targets.
The integration is slated to go live later this year and allow doctors to order Myriad's tests and receive the results in Epic's platform without additional, manual steps.
Branded InSignia, the patented technology will first be incorporated into a gonorrhea antimicrobial susceptibility assay, followed by a point-of-care test.